leisure time -WSS

leisure time

author：explore 2025-10-01 11:33:04 - browse：63314

A syringe injects into a segment of DNA — biotech coverage from STAT — Adobe

Two congenitally deaf children can hear for the first time after being treated with gene therapy, according to data presented at a conference Wednesday.

The results are “jaw-droppingly good, just shocking how good. It exceeded the wildest expectations of anybody who started this work,” said Larry Lustig, an otolaryngologist at Columbia University and an investigator on the study.

The new data come from a larger study by Regeneron Pharmaceuticals that will treat nearly two dozen children with a specific type of congenital hearing loss with gene therapy. The clinical trial is meant to measure safety and efficacy of DB-OTO, a gene therapy drug Regeneron is developing to treat children who have hearing loss due to changes in the otoferlin gene. Several teams are targeting this rare form of congenital deafness that affects 1% to 8% of deaf people globally, including a team with Akouos, an Eli Lilly subsidiary, which successfully treated an 11-year-old boy with a similar gene therapy. Lustig calls this the “lowest of the low-hanging fruit” for gene therapy deafness treatments.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

WSS

Readout Newsletter: XBI biotech index, Akero Therapeutics

Feds fine Medicare Advantage plans for overcharging members

CDC recommends rationing of RSV shot due to shortages

Physician subsidies by hospitals soar in wake of No Surprises Act

Hospitals warn Medicare's drug payment fix is ‘unlawful’

Australia’s approach to dialysis celebrates life

hotspot

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

What does generative AI mean for health care? We asked experts

Medicare explains how it will choose drugs for negotiation

New air purifier tech could be key to improving indoor air quality

Medtronic CEO on promising devices for diabetes, hypertension

ChatGPT in medicine: STAT answers readers' burning questions

WHO may add ‘noma' to its list of neglected tropical diseases

Malaria cases in Florida and Texas: Here’s what you need to know

Hospitals warn Medicare's drug payment fix is ‘unlawful’

Sports medicine is finally prioritizing gender equality

Apellis safety probe of eye disease drug centers on injection needle

leisure time

Diversifying clinical trials isn't enough to close racial gaps: study

Why more medical students aren't specializing in primary care

The FDA weighs the risks of candy

What do new weight loss drugs mean for bariatric surgery?

Paying for Covid pills will soon shift to insurers

Unicorn down: Following layoffs, Biofourmis CEO quietly departs

explore

Wikipedia

focus

hotspot